Research Article

Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment

Min-jie Mao,1 Xiao-li Wei,2 Hui Sheng,3 Xue-ping Wang,1 Xiao-hui Li,1 Yi-jun Liu,1 Shan Xing,1 Qi Huang,4 Shu-qin Dai,1 and Wan-li Liu1

1Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng Road East, Guangzhou, Guangdong Province 510060, China
2Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng Road East, Guangzhou, Guangdong Province 510060, China
3Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng Road East, Guangzhou, Guangdong Province 510060, China
4Guangdong Medical University, 1 Xin Cheng Road, Songshan Hu, Dongguan, Guangdong Province 523808, China

Correspondence should be addressed to Shu-qin Dai; daishq@sysucc.org.cn and Wan-li Liu; liuwanli126@126.com

Received 13 December 2016; Revised 8 March 2017; Accepted 13 March 2017; Published 23 March 2017

Academic Editor: Sabine Rohrmann

Copyright © 2017 Min-jie Mao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The pretreatment albumin and globulin ratio (AGR) was an inflammation-associated factor which was related to the overall survival in various malignancies. The aim of this study was to evaluate the prognostic value of AGR in patients with gastric cancer.

Method. This retrospective study included 862 cases pathologically diagnosed with gastric cancer. All patients were randomly divided into the testing group (431 cases) and validation group (431 cases). The relationships of AGR with clinicopathologic characteristics and prognosis were analyzed by Kaplan-Meier and Cox regression methods.

Results. In the testing group, the median overall survival was 26.90 months and the cutoff value of AGR was 1.50 based on R language. Kaplan-Meier analysis showed that lower AGR was correlated with poorer overall survival. Multivariate analysis demonstrated that AGR was an independent prognostic factor for overall survival (HR: 0.584, 95% CI = 0.351–0.973, and p = 0.039). In the validation group, the median overall survival was 24.10 months. Lower AGR (≤1.50) also had a significantly poorer overall survival by Kaplan-Meier analysis. According to multivariate analysis, the AGR was also confirmed to be an independent prognostic factor for overall survival (HR: 0.578, 95% CI = 0.373–0.897, and p = 0.015).

Conclusions. Our study suggested that the pretreatment AGR could be a prognostic biomarker for overall survival in patients with gastric cancer.

1. Introduction

Gastric cancer (GC) is a common malignant tumor of upper digestive tract. In 2012, the incidence and mortality of GC in the world ranked fifth and third, with approximately 951,000 new cases and 723,000 deaths, respectively [1]. The most common pathologic type is adenocarcinoma [2]. Many techniques, such as the serum CA72-4 level testing and gastroscopy, have been used to screen for GC and assess the risk of recurrence. However, these biomarkers are not sufficient to predict prognosis accurately [3]. The surgical treatment is still the preferred treatment for GC patients without distant metastasis [4]. Although there was great advance in the diagnosis and treatment strategy, the prognosis was still poor; the five-year overall survival was only 4% for patients at stage IV [5]. Currently, the best clinical prognostic indicator for GC is TNM category, but there were still significant differences in prognosis among patients at the same stage [6]. Thus, it is important to look for clinical indicators which were reliable and easily detectable for survival and treatment guidance in GC.

Tumor development and metastasis could be promoted by chronic inflammation [7]. The interaction between tumors and immune system promoted the production of proinflammatory factors, which induced the occurrence of inflammation [8]. Systemic inflammatory response could inhibit
immune surveillance, enhance the permeability of blood vessels and lymphatics, and degrade extracellular matrix by cytokines, chemokines, proangiogen, and active amine, causing tumor development and metastasis [8]. It had been confirmed by previous reports that some inflammatory factors had significant prognostic value in GC, such as NLR (neutrophil/lymphocyte ratio) [9], PLR (platelet/lymphocyte ratio) [10], and CRP (C-reaction protein). Albumin (ALB) and globulin (GLB) were the major protein components in serum, which played an important role in inflammation [11, 12]. A decreased ALB level and increased GLB level had been reported to reflect chronic inflammation. Previously, ALB/GLB ratio (AGR) was mainly used for the diagnosis of liver function and immunological diseases [13]. In recent years, it has been reported as a novel inflammatory indicator for prognosis in colorectal cancer [14], lung cancer [15], esophageal cancer [16], and breast cancer [17]. But the prognostic value of AGR in GC remained to be further investigated.

In this study, we would assess the prognostic value of the pretreatment AGR for overall survival (OS) and evaluate its association with clinicopathologic characteristics and other inflammation-associated factors in GC patients with a large sample.

2. Materials and Methods

2.1. Patients. We retrospectively reviewed the clinical data of 1161 GC patients treated at Sun Yat-sen University Cancer Center, from 2009 to 2013. The main clinical characteristics are described in Table 1. All patients were pathologically diagnosed with GC and classified and staged based on the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system. Exclusion criteria were as follows: (1) patients treated with medication or taking nutrition replacement therapy or any drugs known to affect serum ALB and GLB levels before serum collection; (2) patients with concomitant diseases associated with increased serum ALB and GLB levels (i.e., liver diseases, or metabolic syndrome); (3) other types of malignancy; (4) patients who were lost to follow-up. The serum detection results before initial treatment were all retrospectively obtained from the clinical laboratory. The globulin was calculated by total proteins minus albumin. The AGR was calculated with the equation: albumin/(total proteins – albumin). The NLR and PLR were calculated as neutrophil/lymphocyte ratio and platelet/lymphocyte ratio, respectively. Other clinicopathologic characteristics were retrospectively collected by reviewing medical records. Finally, there were 862 cases included in the study.

2.2. Laboratory Measurements. Peripheral blood was collected from the patients between 7 and 8 a.m., clotted at room temperature, and centrifuged at 3500 r/min for 8 min. The concentrations of albumin and total proteins were measured using a Hitachi 7600 automatic biochemical analyzer (Hitachi High-Technologies, Tokyo, Japan). Albumin and total proteins were measured using colorimetry. All reagents used in this study were provided by Wako Pure Chemical Industries, Japan. The coefficient of variation of the two tests in our laboratory is ≤5%. The levels of neutrophil, lymphocyte, and platelet were derived from the blood count using a Sysmex XE-5000 automatic blood-cell counter (Sysmex Corporation, Kobe, Japan). All the markers were measured before treatment after diagnosis in hospital. Venous blood samples were collected in tubes without anticoagulation at 7 am in the second day in hospital. The samples were centrifuged half an hour later and tested within 2 h of processing according to the instructions from the manufacturer.

2.3. Follow-Up. All patients provided written informed consent for the information to be used in our hospital database. Study approval was obtained from an independent ethics committee at Sun Yat-sen University Cancer Center. This study was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. In our institution, patients were generally followed up every 3 months in the first years, every 6 months for the following 2 years, and annually thereafter. The last follow-up was in June 2016, survival status was verified again through checking clinical attendance records and direct telecommunication with the patients or their family (performed by The Medical Information Unit in our Cancer Center), and all the dead patients died of gastric cancer.

2.4. Statistical Analysis. We divided the patients into the testing group and the validation group with the equal numbers by random assignment. The AGR was categorized using the method reported by Budczies et al. [18]; NLR and PLR were also expressed as the median. The significance of correlations between the pretreatment AGR and the clinicopathologic characteristics was analyzed by χ2 test or Kruskal-Wallis H test. The associations of AGR with NLR and PLR were examined by correlation analysis. OS was the time interval from diagnosis of GC to death or the last follow-up and was analyzed using the Kaplan-Meier method. The differences in OS were assessed with the log-rank test. Univariante and multivariate analyses of clinical variables were performed using Cox proportional hazards regression models. All statistical analyses were performed using the SPSS 17.0 (SPSS Inc., Chicago, IL, USA). A two-tailed p value of <0.05 was considered significant.

3. Results

3.1. Patients’ Baseline Characteristics in GC Patients. In this study, a total of 1161 patients with GC were screened and 862 patients were finally included for analyses. We divided the patients into the testing group (431 cases) and the validation group (431 cases) by random assignment. The clinicopathologic characteristics in each group were presented in Table 1. In the testing group, there were 288 (66.8%) male patients and 143 (33.2%) female patients. The median age was 59 (range: 26–85) years old. The number of patients at stages I, II, III, and IV was 66 (15.3%), 110 (25.5%), 201 (46.6%), and 54 (12.5%), respectively. There were 218 (50.6%) patients with proximal GC, 160 (37.1%) patients with remote GC, and 53 (12.3%) patients with GC in other locations. In the validating group,
Table 1: The clinicopathological characteristics of gastric cancer patients.

| Characteristic                | The testing group | The validation group |
|------------------------------|-------------------|----------------------|
|                              | Median (25th–75th percentile) or number (%) | Median (25th–75th percentile) or number (%) |
| Gender                       |                   |                      |
| Male                         | 288 (66.8)        | 298 (69.1)           |
| Female                       | 143 (33.2)        | 133 (30.9)           |
| Age (years)                  |                   |                      |
| ≤59                          | 222 (51.5)        | 232 (53.8)           |
| >59                          | 209 (48.5)        | 199 (46.2)           |
| TNM category (AJCC, 7th)     |                   |                      |
| I                            | 66 (15.3)         | 58 (13.5)            |
| II                           | 110 (25.5)        | 100 (23.2)           |
| III                          | 201 (46.6)        | 208 (48.3)           |
| IV                           | 54 (12.5)         | 65 (15.1)            |
| N stage (AJCC, 7th)          |                   |                      |
| N0                           | 130 (30.2)        | 141 (32.7)           |
| N1                           | 301 (69.8)        | 290 (67.3)           |
| T stage (AJCC, 7th)          |                   |                      |
| T1                           | 54 (12.5)         | 40 (9.3)             |
| T2                           | 46 (10.7)         | 61 (14.2)            |
| T3                           | 142 (32.9)        | 138 (32.0)           |
| T4                           | 189 (43.9)        | 192 (44.5)           |
| M stage (AJCC, 7th)          |                   |                      |
| M0                           | 366 (84.9)        | 349 (81.0)           |
| M1                           | 65 (15.1)         | 82 (19.0)            |
| Primary tumor size (cm)      |                   |                      |
| <4.0                         | 178 (41.3)        | 171 (39.7)           |
| ≥4.0                         | 253 (58.7)        | 260 (60.3)           |
| Tumor location               |                   |                      |
| Proximal                     | 218 (50.6)        | 239 (55.5)           |
| Remote                       | 160 (37.1)        | 147 (34.1)           |
| Other                        | 53 (12.3)         | 45 (10.4)            |
| Degree of differentiation    |                   |                      |
| Poorly or not differentiated | 253 (58.7)        | 250 (58.0)           |
| Moderately differentiated    | 174 (40.4)        | 179 (41.5)           |
| Well differentiated          | 4 (0.9)           | 2 (0.5)              |
| Tests                        |                   |                      |
| CRP                          | 1.78 (0.12–155.32)| 1.91 (0.12–278.56)  |
| ALB                          | 41.6 (25.1–49.1)  | 41.9 (27.50–51.00)  |
| GLB                          | 27.3 (12.8–41.8)  | 27.45 (16.90–42.00) |
| PLT                          | 240.90 (88.00–869.00) | 235.00 (77.00–641.60) |
| Neutrophil                   | 3.7 (0.7–17.1)    | 3.80 (1.20–19.37)   |
| Lymphocyte                   | 1.6 (0.2–3.7)     | 1.70 (0.23–3.80)    |

there were 298 (69.1%) male and 133 (30.9%) female patients. The median age was 59 (range: 26–85) years old. The number of patients at stages I, II, III, and IV was 58 (13.5%), 100 (23.2%), 208 (48.3%), and 65 (15.1%), respectively. There were 239 (55.5%) patients with proximal GC, 179 (41.5%) patients with remote GC, and 45 (10.4%) patients with GC in other locations.

3.2. The Prognostic Value of AGR for OS in All the GC Patients.
In univariate analysis, age (HR: 1.50, 95% CI = 1.073–1.698, and \( p = 0.010 \)), primary tumor size (HR: 1.779, 95% CI = 1.335–2.370, and \( p < 0.001 \)), tumor location (HR: 1.195, 95% CI = 1.007–1.419, and \( p = 0.042 \)), distant metastasis (HR: 6.113, 95% CI = 4.787–7.807, and \( p < 0.001 \)), surgery (HR: 0.469, 95% CI = 0.358–0.613, and \( p < 0.001 \)), the TNM category
Table 2: Prognostic value of AGR for overall survival in the testing group of GC patients by univariate and multivariate analyses.

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | Hazard ratio | 95% CI       | p value | Hazard ratio | 95% CI       | p value |
| Sex                              |             |               |         |             |               |         |
| Male versus female               | 0.886       | 0.603–1.302   | 0.538   |             |               |         |
| Age (yr) ≤59 versus >59          | 1.313       | 0.922–1.870   | 0.131   |             |               |         |
| Primary tumor size (cm) <4.0 versus ≥4.0 | 1.855     | 1.182–2.909   | 0.007   | 1.451       | 0.828–2.544   | 0.193   |
| Tumor location Proximal versus remote versus other | 1.366     | 1.046–1.784   | 0.022   | 1.224       | 0.864–1.735   | 0.255   |
| Degree of differentiation Poorly versus moderately versus well | 1.080     | 0.560–2.083   | 0.818   |             |               |         |
| Distant metastasis No versus yes | 6.989       | 4.776–10.228  | <0.001  | 2.361       | 1.216–4.585   | 0.011   |
| Surgery No versus yes            | 0.509       | 0.337–0.768   | <0.001  | 1.467       | 0.745–2.887   | 0.268   |
| TNM category (AJCC, 7th) I+II versus III+IV | 4.577     | 2.859–7.326   | <0.001  |             |               |         |
| NLR ≤2.08 versus >2.08           | 1.959       | 1.344–2.855   | <0.001  | 1.269       | 0.748–2.153   | 0.378   |
| PLR ≤140.63 versus >140.63       | 1.923       | 1.330–2.778   | 0.001   | 1.106       | 0.628–1.950   | 0.727   |
| AGR ≤1.50 versus >1.50           | 0.626       | 0.438–0.859   | 0.010   | 0.584       | 0.351–0.973   | 0.039   |

(HR: 5.320, 95% CI = 3.246–8.721, and p < 0.001), ALB (HR: 0.695, 95% CI = 0.552–0.875, and p = 0.002), PLR (HR: 1.730, 95% CI = 1.367–2.190, and p < 0.001), NLR (HR: 1.94, 95% CI = 1.517–2.466, and p < 0.001), and AGR (HR: 0.648, 95% CI = 0.514–0.817, and p < 0.001) were significantly associated with OS. Multivariate analysis (Cox proportional hazards model) identified distant metastasis (HR: 2.247, 95% CI = 1.504–3.356, and p < 0.001), the TNM category (HR: 2.962, 95% CI = 1.627–5.393, and p < 0.001), NLR (HR: 1.442, 95% CI = 1.028–2.023, and p = 0.011), and AGR (HR: 0.630, 95% CI = 0.451–0.879, and p = 0.007) as independent prognostic factors. ALB and GLB were not significantly associated with OS (see Supplement 1 in Supplementary Material available online at https://doi.org/10.1155/2017/3083267).

3.3. The Prognostic Value of AGR for OS in the Testing Group.

The median OS for patients in the testing group was 26.90 months, with a range of 0.20–53.87 months. The median OS for patients with a higher level (>1.50) and lower level (≤1.50) of AGR were 30.00 and 24.10 months, respectively. In univariate analysis, the following factors were significantly associated with OS: primary tumor size (HR: 1.855, 95% CI = 1.182–2.909, and p = 0.007), tumor location (HR: 1.366, 95% CI = 1.046–1.784, and p = 0.022), distant metastasis (HR: 6.989, 95% CI = 4.776–10.228, and p < 0.001), surgery (HR: 0.509, 95% CI = 0.337–0.768, and p < 0.001), the TNM category (HR: 4.577, 95% CI = 2.859–7.326, and p < 0.001), PLR (HR: 1.923, 95% CI = 1.330–2.778, and p = 0.001), NLR (HR: 1.959, 95% CI = 1.344–2.855, and p < 0.001), and AGR (HR: 0.626, 95% CI = 0.438–0.859, and p = 0.001). Multivariate analysis (Cox proportional hazards model) was carried out based on all the potentially prognostic factors identified in univariate analysis above, to evaluate whether these factors were independent prognostic factors for survival. The results identified distant metastasis (HR: 2.361, 95% CI = 1.216–4.585, and p = 0.011) and AGR (HR: 0.584, 95% CI = 0.351–0.973, and p = 0.039) as independent prognostic factors (Table 2).

In the Kaplan-Meier analysis, AGR was significantly associated with OS (Figure 1(a)). For the whole cohort, the OS was 6.25 months shorter in patients with lower AGR (mean, 22.25 months) than those with higher AGR (mean, 28.50 months). As an important prognostic factor for OS, the relationship between AGR and survival was further evaluated according to the clinical stage. The survival rate of patients with decreased AGR levels had a significantly shorter OS compared with those patients with increased AGR levels only in advanced stage subgroup (p = 0.026, Figure 1(c)).

3.4. The Prognostic Value of AGR for OS in the Validation Group.

The median OS for patients in the validation group was 24.10 months, with a range of 0.50–59.57 months. The median OS for patients with a higher level (>1.50) and lower level (≤1.50) of AGR were 27.20 months and 20.00 months, respectively. In univariate analysis, age (HR: 1.015, 95% CI = 1.002–1.029, and p = 0.021), primary tumor size
Figure 1: The prognostic significance of AGR based on the clinical stage in testing and validation group of GC. The five-year overall survival rate was calculated using the Kaplan-Meier method and analyzed with the log-rank test. A lower AGR level experienced significantly shorter overall survival than patients with a normal AGR in the whole cohort (a), stage I-II subgroup (b), and stage III-IV (c) of the testing group. Meanwhile, a lower AGR level experienced significantly shorter overall survival than patients with a normal AGR in the whole cohort (d), stage I-II subgroup (e), and stage III-IV (f) of the validation group in GC.

(HR: 1.713, 95% CI = 1.180–2.487, and p = 0.005), distant metastasis (HR: 5.375, 95% CI = 3.898–7.410, and p = 0.000), surgery (HR: 0.430, 95% CI = 0.307–0.626, and p < 0.001), the TNM category (HR: 6.205, 95% CI = 3.035–12.678, and p < 0.001), PLR (HR: 1.630, 95% CI = 1.199–2.151, and p = 0.002), NLR (HR: 1.946, 95% CI = 1.415–2.676, and p < 0.001), and AGR (HR: 0.649, 95% CI = 0.478–0.882, and p = 0.006) were significantly associated with OS. Multivariate analysis (Cox proportional hazards model) identified distant metastasis (HR: 2.939, 95% CI = 1.781–4.850, and p < 0.001), NLR (HR: 1.766, 95% CI = 1.136–2.745, and p = 0.011), and AGR (HR: 0.578, 95% CI = 0.373–0.897, and p = 0.015) as independent prognostic factors (Table 3).

In the Kaplan-Meier analysis, AGR was also closely associated with OS (Figure 1(d)). For the whole cohort, the OS was 790 months shorter in patients with lower AGR (mean, 19.73 months) than those with higher AGR (mean, 27.63 months), and the relationship between AGR and OS was further evaluated according to the TNM category. Patients with decreased AGR levels had a significantly shorter OS compared with those with increased AGR levels only in advanced stage subgroup (p = 0.008, Figure 1(f)).
Table 3: Prognostic value of AGR for overall survival in the validation group of GC patients by univariate and multivariate analyses.

| Characteristics       | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | Hazard ratio   | 95% CI   | p value | Hazard ratio | 95% CI | p value |
| Sex                   | 1.121            | 0.81–1.552 | 0.49    | 1.080        | 0.705–1.653 | 0.723   |
| Primary tumor size (cm)| 1.713            | 1.180–2.487 | 0.005   | 1.319        | 0.800–2.174 | 0.278   |
| Proximal versus remote | 1.096            | 0.876–1.371 | 0.423   |              |        |        |
| Surgery               | 0.430            | 0.307–0.626 | <0.001  | 0.973        | 0.585–1.620 | 0.917   |
| TNM category          | 6.205            | 3.035–12.678 | <0.001  |              |        |        |
| NLR                   | 1.946            | 1.415–2.676 | <0.001  | 1.766        | 1.136–2.745 | 0.011   |
| AGR                   | 1.630            | 1.199–2.215 | 0.002   | 1.373        | 0.885–2.129 | 0.157   |

4. Discussion

Recently, Chen et al. reported that a low level of GLB might be a significant prognostic marker for worse survival in patients with GC and they also mentioned the prognostic value of AGR in GC [19]. However, there were some limitations in their study. Firstly, they did not explore the relationship between AGR and clinical pathological characteristics of GC patients. Secondly, they only studied the prognostic value of AGR for patients who received radical surgery. For patients who did not receive surgical treatment, the prognostic role of AGR was still not clear. Thirdly, there were only 186 cases in their study; the sample was small. Thus, the prognostic value of AGR in GC was worthy of further study.

In our study, we included 862 cases with and without radical surgical, and the pretreatment AGR was an independent prognostic factor for patients with GC in multivariate analysis in both groups. Furthermore, after stratification by TNM category, preoperative AGR remained significantly prognostic, especially in advanced TNM category patients. Previous studies had reported that chronic inflammation was strongly correlated with the invasion and metastasis of GC [20, 21]. The tumor microenvironment was constituted by inflammatory cells, inflammatory cytokines, and inflammatory chemokines [22]. The formation of tumor microenvironment could lead to the infiltration of immunosuppressive cells such as myeloid derived suppressor cell, regulatory T cell and tumor associated macrophage, upregulation of a series of proinflammatory factors, and accumulation of a large number of inflammatory cytokines such as IL-6, IL-11, TGF-β, and MMP. These cytokines could promote the immune escape and metastasis of tumors by STAT3, NF-κB signal pathway, and so on [23–27].

As clinical routine detection indexes, ALB and GLB were the main proteins in human body. ALB played an important role in material transport and the maintenance of plasma osmotic pressure. It not only reflected the nutritional status of the body, but also represented the level of inflammation [11]. Cytokines, such as IL-6 and TNF, were produced by the inflammatory response, which could inhibit the synthesis of ALB in liver cells [28]. A long term chronic inflammation could lead to vascular endothelial damage and increase vascular permeability, which could increase the level of ALB in interstitial fluid and result in decreasing of serum ALB. Previous studies had confirmed that a low level of ALB was associated with poor prognosis in a variety of malignant tumors, including GC [29], colorectal cancer [30], lung cancer [31], and breast cancer [32]. GLB was produced by immune organs and reflected the immune state [33], which contained a lot of acute reactive proteins such as α₁-antitrypsin, α₂-macroglobulin, and haptoglobin. In the stimulation of inflammation, the level of serum GLB increased rapidly by several inflammatory indicators; it was also correlated with poor prognosis in several malignant tumors [34, 35].

Although previous studies demonstrated ALB and GLB to be significant prognostic factors, which would be influenced by many factors, body dehydration or fluid retention had
great impacts on ALB and GLB levels; however they had little influence on AGR. Previous studies had shown that a decreased pretreatment AGR level predicted poor survival in several malignant tumors [14–17]. In our study, AGR was identified to be an independent prognostic factor for GC after adjusting by confounding prognostic factors in both the testing group and the validation group. These findings proved that pretreatment AGR was a promising inflammatory biomarker that would improve the prognostic value for patients with GC.

In this study, we found that AGR had significant prognostic value in patients with GC. But there were still some limitations in our study. Firstly, prospective studies were needed to confirm our conclusions because it was a retrospective analysis. Secondly, there was no uniform cutoff value for AGR so far, so different statistical methods may obtain different cutoff value, while the method we used was based on the R language, which had been proved by other studies with high reliability.

The present data show that preoperative AGR is strongly associated with overall survival in GC. Both ALB and GLB are convenient low-cost indicators that are routinely measured in clinical practice. Thus, the AGR is highly feasible and is validated in our study. In conclusion, our study demonstrated that AGR is an independent biomarker of poor survival and could be employed as a prognostic tool in patients with GC.

Abbreviations
GC: Gastric cancer
ALB: Albumin
GLB: Globulin
AGR: ALB/GLB ratio
OS: Overall survival.

Disclosure
Min-jie Mao, Xiao-li Wei, and Hui Sheng are co-first authors.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
Wan-li Liu and Shu-qin Dai conceived and designed the experiments. Min-jie Mao, Xiao-li Wei, and Hui Sheng performed the experiments. Xiao-hui Li, Yi-jun Liu, and Shan Xing analyzed the data. Qi Huang contributed reagents/materials/analysis tools. Xue-ping Wang and Min-jie Mao wrote the paper. Min-jie Mao, Xiao-li Wei, and Hui Sheng contributed equally to this work.

Acknowledgments
The authors would like to thank their colleagues for their contribution to this study.

References
[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[2] J. R. Jass, L. H. Sobin, and H. Watanabe, “The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition,” Cancer, vol. 66, no. 10, pp. 2162–2167, 1990.
[3] T. Waddell, M. Verheije, W. Allum, D. Cunningham, A. Cervantes, and D. Arnold, “Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up,” European Journal of Surgical Oncology, vol. 40, no. 5, pp. 584–591, 2014.
[4] G. Tomasello, M. Ghidini, W. Liguigli, M. Ratti, L. Toppo, and R. Passalacqua, “Targeted therapies in gastric cancer treatment: where we are and where we are going,” Investigational New Drugs, vol. 34, no. 3, pp. 378–393, 2016.
[5] H. Jung, H. H. Lee, K. Y. Song, H. M. Jeon, and C. H. Park, “Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer,” Cancer, vol. 117, no. 11, pp. 2371–2378, 2011.
[6] S. G. Thrumurthy, M. A. Chaudry, I. Chau, and W. Allum, “Does surgery have a role in managing incurable gastric cancer?” Nature Reviews Clinical Oncology, vol. 12, no. 11, pp. 676–682, 2015.
[7] L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
[8] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010.
[9] I. R. Cho, J. C. Park, C. H. Park et al., “Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer,” Gastric Cancer, vol. 17, no. 4, pp. 703–710, 2014.
[10] S. Cetinkunar, H. Guzel, I. E. Gokce et al., “High levels of platelet/lymphocyte ratio are associated with metastatic gastric cancer,” Journal of B.U.ON., vol. 20, no. 1, pp. 78–83, 2015.
[11] V. Arroyo, R. Garcia-Martinez, and X. Salvatella, “Human serum albumin, systemic inflammation, and cirrhosis,” Journal of Hepatology, vol. 61, no. 2, pp. 396–407, 2014.
[12] Q. Li, X. Meng, L. Liang et al., “High preoperative serum globulin in rectal cancer treated with neoadjuvant chemoradiation therapy is a risk factor for poor outcome,” American Journal of Cancer Research, vol. 9, pp. 2856–2864, 2015.
[13] A. C. Kibrick and A. B. Clements, “A comparative study of the serum albumin-globulin ratio, the cephalin-cholesterol flocculation, and the thymol turbidity tests for liver function,” The Journal of Laboratory and Clinical Medicine, vol. 33, no. 6, pp. 662–671, 1948.
[14] M. Shibutani, K. Maeda, H. Nagahara et al., “The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer,” BMC Cancer, vol. 15, no. 1, article 347, 2015.
[15] S. Park, S. Park, S.-H. Lee et al., “Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer,” Cancer Biomarkers, vol. 16, no. 3, pp. 425–433, 2016.
[16] F. Zhang, P. Sun, Z.-Q. Wang et al., “Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma,” Oncotarget, vol. 7, no. 21, pp. 30550–30560, 2016.

[17] B. N. Azab, V. R. Bhatt, S. Vonfrolio et al., “Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients,” American Journal of Surgery, vol. 206, no. 5, pp. 764–770, 2013.

[18] J. Budczies, F. Klauschen, B. V. Sinn et al., “Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization,” PLoS ONE, vol. 7, no. 12, Article ID e51862, 2012.

[19] J. Chen, Y. Zhou, Y. Xu, H.-Y. Zhu, and Y.-Q. Shi, “Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients,” Tumor Biology, vol. 37, no. 3, pp. 3905–3911, 2016.

[20] Y. Gao and D. Huang, “The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: a literature review,” Journal of Cancer Research and Therapeutics, vol. 10, no. 4, pp. 799–804, 2014.

[21] Q.-X. Pan, Z.-J. Su, J.-H. Zhang, C.-R. Wang, and S.-Y. Ke, “A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer,” OncoTargets and Therapy, vol. 8, pp. 1375–1385, 2015.

[22] D. F. Quail and J. A. Joyce, “Microenvironmental regulation of tumor progression and metastasis,” Nature Medicine, vol. 19, no. 11, pp. 1423–1437, 2013.

[23] S. B. Coffelt and K. E. De Visser, “Cancer: inflammation lights the way to metastasis,” Nature, vol. 507, no. 7490, pp. 48–49, 2014.

[24] F. Chalmin, G. Mignot, and F. Ghiringhelli, “Myeloid-derived suppressor cells: a key player in cancer,” Médecine/Sciences, vol. 26, no. 6-7, pp. 576–579, 2010.

[25] A. Rojas, F. Delgado-López, and I. Gonzalez, “Tumor-associated macrophages in gastric cancer: more than bystanders in tumor microenvironment,” Gastric Cancer, vol. 20, no. 1, pp. 215–216, 2017.

[26] E. Pikarsky, R. M. Porat, I. Stein et al., “NF-κB functions as a tumour promoter in inflammation-associated cancer,” Nature, vol. 431, no. 7007, pp. 461–466, 2004.

[27] D. Q. Wang, X. P. Ding, S. Yin, and Y. D. Mao, “Role of the IL-11/STAT3 signaling pathway in human chronic atrophic gastritis and gastric cancer,” Genetics and Molecular Research, vol. 15, no. 2, Article ID gmr.15027358, 2016.

[28] C. Pfensig, A. Dominik, L. Borufka, M. Hinz, J. Stange, and M. Eggert, “A new application for albumin dialysis in extracorporeal organ support: characterization of a putative interaction between human albumin and proinflammatory cytokines IL-6 and TNFα,” Artificial Organs, vol. 40, no. 4, pp. 397–402, 2016.

[29] K. Yamashita, H. Ushiku, N. Katada et al., “Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test,” European Journal of Surgical Oncology, vol. 41, no. 10, pp. 1324–1332, 2015.

[30] T. Fujii, T. Sutoh, H. Morita et al., “Serum albumin is superior to prealbumin for predicting short-term recurrence in patients with operable colorectal cancer,” Nutrition and Cancer, vol. 64, no. 8, pp. 1169–1173, 2012.

[31] O. Arrieta, R. M. Michel Ortega, G. Villanueva-Rodriguez et al., “Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study,” BMC Cancer, vol. 10, article 50, 2010.

[32] X. Liu, Q. H. Meng, Y. Ye, M. A. T. Hildebrandt, J. Gu, and X. Wu, “Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic breast cancer,” Carcinogenesis, vol. 36, no. 2, pp. 243–248, 2015.

[33] M. Ballow, “Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases," Journal of Allergy and Clinical Immunology, vol. 100, no. 2, pp. 151–157, 1997.

[34] L. Adly, D. Hill, M. E. Sherman et al., “Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women," International Journal of Cancer, vol. 119, no. 10, pp. 2402–2407, 2006.

[35] N. Sawada, M. Iwasaki, M. Inoue et al., “Plasma testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer among Japanese men: a nested case-control study," Cancer Science, vol. 101, no. 12, pp. 2652–2657, 2010.